Bath Savings Trust Co Lowers Stake in IDEXX Laboratories, Inc. (IDXX)

Bath Savings Trust Co cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,149 shares of the company’s stock after selling 1,485 shares during the period. IDEXX Laboratories accounts for about 1.3% of Bath Savings Trust Co’s holdings, making the stock its 28th biggest position. Bath Savings Trust Co’s holdings in IDEXX Laboratories were worth $4,843,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. WMS Partners LLC grew its position in shares of IDEXX Laboratories by 0.3% during the second quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after acquiring an additional 4 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of IDEXX Laboratories by 0.3% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after acquiring an additional 19 shares during the last quarter. CAPROCK Group Inc. grew its position in shares of IDEXX Laboratories by 2.2% during the second quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock worth $295,000 after acquiring an additional 40 shares during the last quarter. Strs Ohio grew its position in shares of IDEXX Laboratories by 0.7% during the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after acquiring an additional 41 shares during the last quarter. Finally, National Asset Management Inc. grew its position in shares of IDEXX Laboratories by 2.1% during the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after acquiring an additional 42 shares during the last quarter. Institutional investors and hedge funds own 87.58% of the company’s stock.

A number of brokerages have recently issued reports on IDXX. Stifel Nicolaus restated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research report on Wednesday, August 2nd. Canaccord Genuity restated a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective on the stock in a research report on Wednesday, July 19th. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a research report on Wednesday, August 23rd. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $174.00.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/17/bath-savings-trust-co-lowers-stake-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 0.49% during trading on Tuesday, reaching $159.32. 64,409 shares of the company were exchanged. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01. The stock has a market capitalization of $13.90 billion, a PE ratio of 54.81 and a beta of 0.48. The firm’s 50 day moving average is $156.99 and its 200 day moving average is $160.01.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. During the same quarter in the prior year, the business posted $0.74 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. Analysts expect that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

In other news, Chairman Jonathan W. Ayers sold 17,000 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $154.54, for a total value of $2,627,180.00. Following the completion of the transaction, the chairman now owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. In the last three months, insiders sold 151,734 shares of company stock valued at $23,436,626. Company insiders own 2.77% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply